Infrared-emitting, peptidase-resistant fluorescent ligands of the bradykinin B2 receptor: application to cytofluorometry and imaging
Open Access
- 26 September 2016
- journal article
- research article
- Published by Springer Nature in BMC Research Notes
- Vol. 9 (1) , 1-10
Abstract
We have previously reported the design, pharmacological properties and imaging application of bradykinin (BK) B2 receptor (B2R) ligands conjugated with fluorophores such as fluorescein derivatives at their N-terminus. To take advantage of the high penetration of infrared light into living tissues and their low autofluorescence in this region of the spectrum, additional probes conjugated with cyanine dye 7 (Cy7) were synthesized and characterized. The antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-BK) and the agonist B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-BK) were N-terminally extended with the infrared fluorophore Cy7, producing the peptides B-10665 and B-10666, respectively. Pharmacological studies indicated that the agonist B-10666 lost much affinity for the B2R vs. the parent peptide, whereas the antagonist B-10665 better retained its potency vs. B-9430 (competition of [3H]BK binding to human B2R, contractility of the human isolated umbilical vein for which potency losses were more important in each case). Both probes stained HEK 293 cells that expressed the B2R-green fluorescent protein (GFP) construction in a specific manner (confocal microscopy) and with very extensive co-localization of the green and infrared fluorescence in either case. The agonist B-10666 at 100 nM promoted the endocytosis of B2R-GFP in live cells, but not the antagonist version at 10–25 nM. The Cy7-labeled peptides did not label cells expressing the β2-adrenoceptor-GFP construction. B-10665 at low nanomolar concentrations was an effective probe for the recombinant B2Rs in cytofluorometry and macroscopic imaging of cell wells (IVIS imaging system operated for infrared fluorescence detection). Despite a propensity for non-specific binding when used at high concentrations and limited sensitivity, Cy7-conjugated peptidase-resistant B2R ligands support original imaging and cytofluorometric applications.Keywords
Funding Information
- Fonds de recherche du Québec-Santé (Studentship)
- Canadian Institutes of Health Research (CA) (MOP-93773)
This publication has 14 references indexed in Scilit:
- Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2receptorsPharmacology Research & Perspectives, 2015
- Inhibitory effects of cytoskeleton disrupting drugs and GDP-locked Rab mutants on bradykinin B2 receptor cyclingPharmacological Research, 2013
- Design of Fluorescent Bradykinin Analogs: Application to Imaging of B2 Receptor-Mediated Agonist Endocytosis and Trafficking and Angiotensin-Converting EnzymeThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Vascular smooth muscle contractility assays for inflammatory and immunological mediatorsInternational Immunopharmacology, 2010
- A fluorescent version of the bradykinin B2 receptor antagonist B-9430: Pharmacological characterization and use in live cell imagingPeptides, 2008
- Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin‐mediated angioedemaBritish Journal of Pharmacology, 2008
- B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) Is an Inactivation-Resistant Agonist of the Bradykinin B2 Receptor Derived from the Peptide Antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): Pharmacologic Profile and Effective Induction of Receptor DegradationThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Antagonist-Induced Intracellular Sequestration of Rabbit Bradykinin B2ReceptorHypertension, 2000
- Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET)Proceedings of the National Academy of Sciences, 2000
- Effects of peptide and nonpeptide antagonists of bradykinin B2 receptors on the venoconstrictor action of bradykinin.The Journal of Pharmacology and Experimental Therapeutics, 1994